1606166-80-6Relevant academic research and scientific papers
3,3-Difluoro-3,4,5,6-tetrahydropyridin-2-amines: Potent and permeable BACE-1 inhibitors
Gijsen, Harrie JM,Oehlrich, Daniel,Peschiulli, Aldo,Rombouts, Frederik,Vos, Ann
, (2020)
Since its discovery in 1999, BACE-1, a membrane anchored aspartyl protease expressed primarily in the CNS, has been the target of numerous medicinal chemistry research programs. These efforts have produced highly potent inhibitors with nanomolar affinity
6-AMINO-5-FLUORO-5-(FLUOROMETHYL)-2,3,4,5-TETRAHYDROPYRIDIN-2-YL-PHENYL-5-(METHOXY-D3)-PYRAZINE-2-CARBOXAMIDES AND FLUORINATED DERIVATIVES THEREOF AS BACE1 INHIBITORS
-
Page/Page column 19-20, (2018/07/29)
The invention provides amidine compounds of Formula (I) for the treatment of neurodegenerative or cognitive diseases, including Alzheimer's Disease.
2-AMINO-3-FLUORO-3-(FLUOROMETHYL)-6-METHYL-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINS AS BACE1 INHIBITORS
-
Page/Page column 35, (2017/03/08)
The present invention provides compounds of Formula (I) for the treatment of neurodegenerative or cognitive diseases. The method further provides for piperidine-2-one and piperidine-2-thione intermediates to compounds of formula (I).
COMBINATION TREATMENT COMPRISING ADMINISTRATION OF 2-AMINO-3,5,5-TRIFLUORO-3,4,5,6-TETRAHYDROPYRIDINES
-
Page/Page column 25; 26, (2017/03/08)
The present invention is directed to the combined use of BACE1 inhibitor of Formula (I) and a compound useful in active or passive Tau immunotherapy, a compound useful in active or passive Aβ peptide immunotherapy, an NMDA receptor antagonists, an acetylcholine esterase inhibitor, an antiepileptic, an anti-inflammatory drug, a Tau aggregation inhibitor or an SSRI for the treatment of neurodegenerative or cognitive disorders.
2-AMINO-3,5-DIFLUORO-3,6-DIMETHYL-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS FOR TREATING ALZHEIMER'S DISEASE
-
Page/Page column 23, (2016/06/13)
The present invention is directed to compounds according to Formula (I) which compounds are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds t
IAP ANTAGONISTS
-
Paragraph 0299, (2015/09/23)
There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, util
